• Home
  • About TenNor
  • R&D
  • News
  • Join us
  • Contact us
  • ABOUT
  • R&D
  • NEWS
  • JOIN US
  • CONTACT
中文
菜单
Overview
BOD
SAB
Team
Pipeline
Technology
Medical Needs
Partnering
Expand Access Policy
Company
Innovation
Industry
Culture
Join Us
Contact
  • Home
  • About TenNor
  • R&D
  • News
  • Join us
  • Contact us
NEWS
  1. HOME
  2. NEWS
  • Company
  • Innovation
  • Industry
Company
  • 2024 / 05 / 30
    Rifasutenizol is Recognized in Advancing Research in Women’s Health
    May 30, 2024 - May 28th is The International Day of Action for Women’s Healthcare to raise awareness for diseases and conditions that affect women’s physical and emotional health. The Journal of Medicinal Chemistry published a special Collection and showcased 17 articles that address the ongoing research dedicated to the unmet medical needs in women’s healthcare. TenNor’s article “Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens” was chosen for inclusion in the Collection and recognized in advancing research in women’s healthcare.
  • 2024 / 02 / 14
    The Lancet Infectious Diseases Publishes Rifasutenizol for H. pylori Phase I/II Clinical Trial Results
    Suzhou China, February 14, 2024 – TenNor Therapeutics and the First Hospital of Jilin University jointly published a research article in The Lancet Infectious Diseases (Lancet ID), reporting the phase I/II clinical trial results of rifasutenizol (TNP-2198) for the treatment of Helicobacter pylori (H. pylori) infection. The journal also published a commentary on the research by leading experts in the field.
  • 2023 / 12 / 28
    TenNor Receives IND Approval for TNP-2092 Ointment for the Treatment of Diabetic Foot Infections
    December 28, 2023 – The National Medical Products Administration (NMPA) approved TNP-2092 ointment to conduct a Phase I/II clinical trial for the treatment of diabetic foot infection (DFI).
  • 2023 / 12 / 12
    TenNor Reports Positive Results from Interim Analysis of Rifasutenizol Phase III Clinical Trial
    Suzhou/China, December 12, 2023 – TenNor Therapeutics reports positive results from interim analysis of rifasutenizol (TNP-2198) phase III clinical trial for the treatment of Helicobacter pylori (H. pylori) infection.
  • 2023 / 10 / 13
    Rifasutenizole for H. pylori is Granted Fast Track by the FDA
    Suzhou, China, October 13, 2023 – TenNor Therapeutics announced that its investigational new drug rifasutenizole (TNP-2198) for the treatment of H. pylori infection had been granted Fast Track designation by the FDA.
  • 2023 / 09 / 15
    TenNor Received IND Approval from NMPA for Its Intraarticular Drug TNP-2092 for the Treatment of Prosthetic Joint Infections
    September 13, 2023 – TenNor Therapeutics announced that the National Medical Products Administration (NMPA) has approved the Phase I/II clinical trial of TNP-2092 for intra-articular injection (TNP-2092 IA) for the treatment of prosthetic joint infections (PJI).
  • 2023 / 05 / 20
    Rifasutenizole for H. pylori Completed First Patient in of Phase III Clinical Trials in China
    Suzhou, China, May 20, 2023 – TenNor Therapeutics (Suzhou) Limited announced that its investigational new drug Rifasutenizole (TNP-2198) for the treatment of Helicobacter pylori infection has completed the first patient in (FPI) of a multi-center phase III trials in China.
  • 2023 / 04 / 13
    Rifasutenizole for H. pylori Received FDA QIDP Designation
    Suzhou, China, April 11, 2023 – TenNor Therapeutics (Suzhou) Limited announced that its investigational new drug Rifasutenizole (TNP-2198) for the treatment of Helicobacter pylori infection has been granted the Qualified Infectious Drug Product (QIDP) status by the US FDA.
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • »
  • HOME

    ABOUT

    R&D

  • NEWS

    JOIN US

    CONTACT

  • Address:218 Xinghu Street, Building B7, Suite 701, Suzhou Industrial Park, China.

    Telephone:+86 512-8686-1990

    E-mail:info@tennorx.com

©2023 TENNOR All Rights Reserved. 苏ICP备2025193688号    Design by Eastdays
隐私权政策